AI assistant
PDS Biotechnology Corp — Director's Dealing 2015
Oct 1, 2015
34613_dirs_2015-09-30_29711d9a-dca6-462e-bb18-c87b97621981.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-09-30
Reporting Person: Vaish Renu (V.P., Global Reg. Affairs)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to purchase) | $5.13 | 2025-01-05 | Common Stock (120605) | Direct | |
| Stock Option (right to purchase) | $6.36 | 2025-03-11 | Common Stock (36547) | Direct |
Footnotes
F1: This option, representing a right to purchase a total of 120,605 shares of Common Stock, will become exercisable on January 5, 2016, with 25% vesting on that date and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.
F2: This option, representing a right to purchase a total of 36,547 shares of Common Stock, will become exercisable on March 11, 2016, with 25% vesting on that date and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.